Glucagon-like peptide-1 (GLP-1) agonists have been recently approved as new therapeutic agents for patients with diabetes, based on evidence that GLP-1 agonists can stimulate glucose dependent insulin secretion from the β-cells of pancreatic islets [10]. Here, GLP1R is linked to diabetes mellitus.